Action Roche (QX) - RHHBY

Roche Holdings Ltd AG (QX) (RHHBY) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

51,65

( 0,58% )

Prix Achat

51,33

Prix Vente

52,26

Volume échangé

787 643

51,25 Fourchette du Jour 51,94

37,51 Plage de 52 semaines 60,85

Cap du marché

41,094B

Clôture Veille

51,35

Ouverture

51,5299

Dernière Transaction

786

51.797481

(formt)

Dernière heure de transaction

Volume financier

US$ 40 720 734

VWAP

51,6995

Volume moyen (3 m)

US$ 1 008 386

Actions en circulation

795 617 637

Rendement du Dividende (LTM)

9,8 (3,11%)

Ratio Cours sur Bénéfices

19,88

Bénéfice par action (BPA)

16,04

Chiffre d'affairess (LTM)

63,36B

Bénéfice net (LTM)

12,88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. Show more

Secteur

Healthcare

Industrie

Pharmaceuticals

Site Web

www.roche.com

Siège social

Basel, Switzerland

Fondé

1896

Roche Holdings Ltd AG (QX) est coté dans le secteur Healthcare de la OTC Markets avec le ticker RHHBY. Le dernier cours de clôture d'Roche (QX) était de US$51,35. Au cours de la dernière année, les actions de Roche (QX) ont été négociées dans une fourchette de prix de US$ 37,51 à US$ 60,85.

Roche (QX) compte actuellement 795 617 637 actions en circulation. La capitalisation boursière d'Roche (QX) est de US$41,09 milliard. Roche (QX) a un ratio cours/bénéfice (ratio PE) de 19.88.

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Filing acceptance is based on the Phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50...

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and...

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of...

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for...

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for...

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Filing acceptance, under priority review, based on Phase III data showing giredestrant reduced the risk of invasive disease recurrence or death...

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss...

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all...

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

First approved ctDNA MRD-guided therapy reinforcing Genentech’s commitment to innovation and practice-changing precision medicine New treatment...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.16	0.310739949505	51.49	51.94	49.47	1896115	50.85290861	DR
4	-0.14	-0.270322456073	51.79	53.54	48.1	1988441	51.22948656	DR
12	2.8	5.7318321392	48.85	53.54	47.05	2240179	50.68898583	DR
26	1.98	3.98630964365	49.67	60.85	47.05	2520203	52.96674439	DR
52	10.01	24.0393852065	41.64	60.85	37.51	2086608	49.09673662	DR
156	12.81	32.9814624099	38.84	60.85	29.2	2090917	40.68683048	DR
260	4.11	8.64535128313	47.54	60.85	27.95	1880556	41.37601294	DR

RHHBY - Frequently Asked Questions (FAQ)

What is the current Roche Holdings Ltd AG (QX) share price?

The current share price of Roche Holdings Ltd AG (QX) is US$ 51,65

How many Roche Holdings Ltd AG (QX) shares are in issue?

Roche Holdings Ltd AG (QX) has 795 617 637 shares in issue

What is the market cap of Roche Holdings Ltd AG (QX)?

The market capitalisation of Roche Holdings Ltd AG (QX) is USD 41,09B

What is the 1 year trading range for Roche Holdings Ltd AG (QX) share price?

Roche Holdings Ltd AG (QX) has traded in the range of US$ 37,51 to US$ 60,85 during the past year

What is the PE ratio of Roche Holdings Ltd AG (QX)?

The price to earnings ratio of Roche Holdings Ltd AG (QX) is 19,88

What is the cash to sales ratio of Roche Holdings Ltd AG (QX)?

The cash to sales ratio of Roche Holdings Ltd AG (QX) is 4,01

What is the registered address of Roche Holdings Ltd AG (QX)?

The registered address for Roche Holdings Ltd AG (QX) is Grenzacherstrasse 124, Basel, Basel-Stadt, 4070

What is the Roche Holdings Ltd AG (QX) website address?

The website address for Roche Holdings Ltd AG (QX) is www.roche.com

Which industry sector does Roche Holdings Ltd AG (QX) operate in?

Roche Holdings Ltd AG (QX) operates in the Pharmaceuticals sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roche Holdings Ltd AG (QX) (RHHBY)

Roche Holdings Ltd AG (QX) (RHHBY) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Roche Holdings Ltd AG (QX)

RHHBY Dernières nouvelles

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Genentech Highlights New Breast Cancer and Precision Oncology Data Ahead of ASCO 2026 (RHHBY)

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

RHHBY - Frequently Asked Questions (FAQ)

RHHBY Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités